Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
OFFICE OF THE VICE PRESIDENT
WASHINGTON
February 21, 1996
Michael Riordan
President and Chairman ofthe Board
Gilead Scienc...
THE WIHTE HOUSE
Office of the Press Secretary
For Immediate Release February 21, 1996
Vice President Gore Says Meeting Wit...
themselves from HIV infection.
The Vice President will facilitate ongoing discussions between the government and the
pharm...
Michael L Riordan, Gilead's Founder and CEO, with Vice President Al Gore at Meeting on Accelerating AIDS Treatments
Upcoming SlideShare
Loading in …5
×

Michael L Riordan, Gilead's Founder and CEO, with Vice President Al Gore at Meeting on Accelerating AIDS Treatments

11,315 views

Published on

Dr. Michael L Riordan, Gilead Chairman/CEO, and Vice President Al Gore. Correspondence and Photo: February 1996, three months after Gilead and NIH scientists reported in Science Magazine that Gilead's drug tenofovir [Viread, a key constituent of Truvada], gave 100% protection in a monkey model of AIDS/HIV.

Published in: Health & Medicine
  • Dating direct: ❶❶❶ http://bit.ly/36cXjBY ❶❶❶
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Dating for everyone is here: ❶❶❶ http://bit.ly/36cXjBY ❶❶❶
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Please, how can I contact the person who published this document?
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here

Michael L Riordan, Gilead's Founder and CEO, with Vice President Al Gore at Meeting on Accelerating AIDS Treatments

  1. 1. OFFICE OF THE VICE PRESIDENT WASHINGTON February 21, 1996 Michael Riordan President and Chairman ofthe Board Gilead Sciences, Inc. 353 Lakeside Drive Foster City, CA 94404 Dear Dr. Riordan, Thank you very much for coming to the White House on Tuesday, February 20th to meet with me to discuss drug development for vaccines, therapeutics and microbicides to combat the AIDS virus. I found the discussion to be thought-provoking and insightful. The wisdom and experience you brought to the table was quite helpful in moving our discussion forward and I appreciate your candid comments and suggestions. I plan to stay involved in this issue and look forward to working with you again in thefuture. AI Gore AG/td PRINTED ON RECYCLED PAPER
  2. 2. THE WIHTE HOUSE Office of the Press Secretary For Immediate Release February 21, 1996 Vice President Gore Says Meeting With Pharmaceutical Firms, AIDS Researchers An Important Step in Fight Against Disease Highlighting his and President Clinton's commitment to AIDS drug development, Vice President Gore met Tuesday (2/20) with pharmaceutical company representatives and leading government researchers. He said the private and public sectors should accelerate their joint effort to find and develop as quickly as possible AIDS vaccines, therapeutics, and microbicides. Attending the meeting were representatives of 11 pharmaceutical companies and leading AIDS researchers and officials from the National Institutes of Health, the Department of Defense, and the Food and Drug Administration. They discussed ways to accelerate the development of AIDS vaccines, therapeutics, and microbicides. "This meeting was an important step in strengthening the goverrunent-industry partnership that is essential to finding and developing effective treatments-- and ultimately a cure-- for AIDS," Vice President Gore said. "We are committed to marshalling our best minds and resources in the fight against AIDS." At the December 6, 1995, White House Conference on HIV and AIDS, President Clinton asked Vice President Gore to convene this meeting to "identify all the ways in which we might accelerate the development of vaccines, therapeutics, and microbicides that can protect people from HIV and the infections it causes!' The meeting reflects President Clinton's commitment to bring the AIDS epidemic to an end. • In his three years in office, President Clinton has increased funding for AIDS research by 26 percent, expedited AIDS drug approval, and strengthened the Office of AIDS Research at the National Institutes of Health. At the conclusion of the two-hour meeting, Vice President Gore announced the following steps: The Administration will join with pharmaceutical manufacturers, health insurance companies and other third-party payers, and patient advocacy organizations to develop a collaborative system of clinical trials of AIDS drugs that have been approved by the FDA under expedited procedures to determine the best uses and the long-term effectiveness of those drugs. The Administration will work with international organizations-- such as the World Bank~- to increase investment in AIDS vaccine development and trials worldwide. • The Administration will help facilitate the development of microbicides to enable women to protect
  3. 3. themselves from HIV infection. The Vice President will facilitate ongoing discussions between the government and the pharmaceutical industry to identify promising areas of AIDS research that the government can support. in order to stimulate private sector investment in the next generation of AIDS vaccines, therapeutics, and microbicides. The Food and Drug Administration vvill pursue additional measures to increase the number of anti-HIV therapeutics with pediatric indications. Participants in Vice President Gore's Meeting with Pharmaceutical Companies and AIDS Researchers 2/20/96 The following pharmaceutical company representatives participated in the February 20 meeting on AIDS drug development with Vice President Gore: Anne-Marie Comer President, Chief Executive Officer BIOSYN Manuel Navia, PhD Vice President, Senior Scientist Vertex Pharmaceuticals Inc. Michael Riordan President, Chairman Gilead Sciences Joseph Pittelli Senior Vice President for Clinical Research Wyeth-Ayerst Research George Morrow Group Vice President, Commercial Operations Glaxo Wellcome, Inc. Dan Hoth Senior Vice President, Chief Operating Officer Cell Genesys, Inc. Peter Johnson President, Chief Executive Officer Agouron Pharmaceuticals, Inc. Patrick Zenner President,. Chief Executive Officer Hoffman-La·Roche Rajen Dalal Vice President for Corporate Planning and Business Development Chiron Corporation David Pizzuti Vice President for Anti-Infective Development and Medical Affairs Abbott Laboratories Eve Slater Senior Vice President for Clinical and Regulatory Development Merck

×